The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
Aenova, a contract development and manufacturing organization, announced on June 27, 2025 that it is expanding its sterile manufacturing facility in Latina, Italy with a new cold chain warehouse that will be connected to the existing facility. The new warehouse will support a wide range of cold chain products without the need for special adaptations for specific APIs or countries and will help the company provide end-to-end integrated supply chain solutions for temperature-sensitive pharmaceutical products.
The new warehouse will be 6500 cubic meters, have a total capacity of 1300 pallet spaces, and will maintain a controlled temperature range of 2–8 ºC that will be continuously monitored via a supervisory control and data acquisition system in compliance with current good manufacturing practices (CGMP). An additional area will accommodate 100 pallet spaces dedicated to packing, shipping, and final product preparation.
The warehouse will have the capability to precisely track the location and movement of pallets via a fully automated digital system. An Automated Guided Vehicle system will move goods between production and storage areas. All time-of-refrigerator data will be digitally recorded, and two independent refrigeration systems will ensure uninterrupted operations by backing each other up, therefore providing business continuity. Drug substances will be stored in a dedicated freezer, and state-of-the-art technologies will also enhance energy efficiency and sustainability.
“This expansion significantly enhances our biologics and sterile drug product offering,” Paolo Abbate, managing director at the Aenova site in Latina, said in a press release (1). “By integrating cold chain storage directly into our manufacturing site, we can now offer our customers secure and streamlined logistics; this is a real competitive advantage in terms of speed, reliability, and compliance.”
Construction on the new warehouse began in early 2025, and the company expects the facility to be operational in the first quarter of 2026. An expansion of the Latina site’s fill/finish line for biologics is also planned for the future.
In other Aenova news, the company launched its Aenovation program for the acceleration of drug development in May 2025 (2). The program is designed to fast-track early development of drug formulations, especially to combat bioavailability and solubility challenges. The program deploys a science-based rational selection of formulation and technology and approaches pre-formulation and development in the following three steps:
“Aenova’s extended range of development services allows us to support pharmaceutical and biotech companies in accelerating their programs and optimizing their resources,” Florent Bordet, chief scientific officer at Aenova, said at the time in a press release (2). “Our Aenovation program is a reflection of our commitment to innovation and excellence in pharmaceutical development.”
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
